Clinical Trials Logo

Clinical Trial Summary

This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.


Clinical Trial Description

This is a phase 2 study involving a 1:1 randomization of 40 patients with recurrent or refractory pediatric ependymoma who will receive either erlotinib or oral etoposide. ;


Study Design


Related Conditions & MeSH terms

  • Ependymoma
  • Recurrent or Refractory Pediatric Ependymoma

NCT number NCT01032070
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Terminated
Phase Phase 2
Start date September 27, 2010
Completion date November 26, 2012